PROCAPP, NCT01626781: A Randomized, Open-label Phase III Trial of Mapisal® Versus an Urea Hand-foot Cream as Prophylaxis for Capecitabine-induced Hand-foot Syndrome in Patients With Gastrointestinal Tumors or Breast Cancer |
|
|
| No Longer Available | 3 | | Europe | Mapisal, Urea hand-foot cream | AIO-Studien-gGmbH | the Treatment Hand-foot Syndrome Patients With Gastrointestinal Tumors or Breast Cancer, Who Are Treated With Capecitabine | | | | |
